[go: up one dir, main page]

WO2013093629A3 - Modular vaccines, methods and compositions related thereto - Google Patents

Modular vaccines, methods and compositions related thereto Download PDF

Info

Publication number
WO2013093629A3
WO2013093629A3 PCT/IB2012/003006 IB2012003006W WO2013093629A3 WO 2013093629 A3 WO2013093629 A3 WO 2013093629A3 IB 2012003006 W IB2012003006 W IB 2012003006W WO 2013093629 A3 WO2013093629 A3 WO 2013093629A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
vaccines
treatment
compositions related
modular
Prior art date
Application number
PCT/IB2012/003006
Other languages
French (fr)
Other versions
WO2013093629A2 (en
Inventor
Koen OOSTERHUIS
Jan Batist Anna Gerardus HAANEN
Antonius Nicolaas Maria Schumacher
Original Assignee
Netherlands Cancer Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Netherlands Cancer Institute filed Critical Netherlands Cancer Institute
Publication of WO2013093629A2 publication Critical patent/WO2013093629A2/en
Publication of WO2013093629A3 publication Critical patent/WO2013093629A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to the field of methods and related compositions for the preparation and administration of vaccines, such as DNA vaccines, for the treatment of one or more diseases. In other embodiments, the invention relates to the field of methods for the prevention or treatment of disease comprising administration of one or more vaccines, such as DNA vaccines, for the treatment of a disease to a patient in need thereof. In a particular embodiment, the invention provides a DNA vaccine for the prevention and treatment of HPV and/or an HPV -induced cancer.
PCT/IB2012/003006 2011-12-20 2012-12-19 Modular vaccines, methods and compositions related thereto WO2013093629A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161577811P 2011-12-20 2011-12-20
US61/577,811 2011-12-20

Publications (2)

Publication Number Publication Date
WO2013093629A2 WO2013093629A2 (en) 2013-06-27
WO2013093629A3 true WO2013093629A3 (en) 2014-01-16

Family

ID=48014103

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2012/003006 WO2013093629A2 (en) 2011-12-20 2012-12-19 Modular vaccines, methods and compositions related thereto

Country Status (1)

Country Link
WO (1) WO2013093629A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017524357A (en) 2014-07-16 2017-08-31 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． Chimeric polynucleotide

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002012281A2 (en) * 2000-08-03 2002-02-14 Johns Hopkins University Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US4394448A (en) 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4769331A (en) 1981-09-16 1988-09-06 University Patents, Inc. Recombinant methods and materials
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US5338683A (en) 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US5505941A (en) 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
CA1247080A (en) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
IE872748L (en) 1986-10-16 1988-04-16 Arjomari Europ Polypeptides derived from the evvelope gene of human¹immunodeficiency virus in recombinant baculovirus infected¹insect cells
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
IL86724A (en) 1987-06-19 1995-01-24 Siska Diagnostics Inc Method and kits for the amplification and detection of nucleic acid sequences
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
DE68908054T2 (en) 1988-01-21 1994-03-10 Genentech Inc REINFORCEMENT AND DETECTION OF NUCLEIC ACID SEQUENCES.
CA1340807C (en) 1988-02-24 1999-11-02 Lawrence T. Malek Nucleic acid amplification process
US5130238A (en) 1988-06-24 1992-07-14 Cangene Corporation Enhanced nucleic acid amplification process
EP0386185A1 (en) 1988-07-29 1990-09-12 IntraCel Corporation Method for the genetic expression of heterologous proteins by cells transfected in vivo
CA2003300A1 (en) 1988-11-21 1990-05-21 Franklin Volvovitz Skin test and test kit for aids
US5238944A (en) 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5552143A (en) 1989-03-24 1996-09-03 The Wistar Institute Of Anatomy & Biology Recombinant cytomegalovirus vaccine
US5591439A (en) 1989-03-24 1997-01-07 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
GB9001766D0 (en) 1990-01-25 1990-03-28 Univ Court Of The University O Vaccines
US5514375A (en) 1990-08-15 1996-05-07 Virogenetics Corporation Flavivirus recombinant poxvirus vaccine
MY109299A (en) 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
US5997878A (en) 1991-03-07 1999-12-07 Connaught Laboratories Recombinant poxvirus-cytomegalovirus, compositions and uses
DE69233158T2 (en) 1991-03-07 2004-05-13 Connaught Technology Corp., Greenville GENETICALLY MANUFACTURED STRAIN FOR VACCINES
US5169766A (en) 1991-06-14 1992-12-08 Life Technologies, Inc. Amplification of nucleic acid molecules
US5650398A (en) 1992-07-02 1997-07-22 Cambridge Biotech Corporation Drug delivery enhancement via modified saponins
US5846945A (en) 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
US6485729B1 (en) 1993-09-13 2002-11-26 Protein Sciences Corporation Neuraminidase-supplemented compositions
SK284119B6 (en) 1994-12-24 2004-09-08 Cambridge University Technical Services Limited Use of nucleic acid, composition and method for the preparation thereof
FR2728795B1 (en) 1994-12-30 1997-03-21 Rhone Merieux AVIAN RECOMBINANT LIVING VACCINE USING AVIAN HERPES VIRUS AS A VECTOR
FR2741806B1 (en) 1995-11-30 1998-02-20 Rhone Merieux RECOMBINANT LIVING VACCINE BASED ON TYPE 1 FELINE HERPESVIRUS, PARTICULARLY AGAINST FELIN INFECTIOUS PERITONITIS
FR2750865B1 (en) 1996-06-27 1998-12-04 Rhone Merieux RECOMBINANT LIVING VACCINE BASED ON CANINE HERPESVIRUS, IN PARTICULAR FOR SQUARE DISEASE, RABIES OR TYPE 2 PARAINFLUENZA VIRUS
FR2750866B1 (en) 1996-06-27 1998-11-27 Rhone Merieux AVIAN RECOMBINANT LIVING VACCINE USING AVIAN INFECTIOUS LARYNGOTRACHEITIS VIRUS
US6090393A (en) 1996-07-03 2000-07-18 Merial Recombinant canine adenoviruses, method for making and uses thereof
FR2751224B1 (en) 1996-07-19 1998-11-20 Rhone Merieux POLYNUCLEOTIDE VACCINE FORMULA AGAINST BREATHING AND PIG REPRODUCTIVE CONDITIONS
FR2751226B1 (en) 1996-07-19 1998-11-27 Rhone Merieux POLYNUCLEOTIDE VACCINE FORMULA AGAINST HORSE PATHOLOGIES
FR2751225B1 (en) 1996-07-19 1998-11-27 Rhone Merieux AVIAN POLYNUCLEOTIDE VACCINE FORMULA
FR2751227B1 (en) 1996-07-19 1998-11-27 Rhone Merieux POLYNUCLEOTIDE VACCINE FORMULA AGAINST CANINE CONDITIONS, ESPECIALLY RESPIRATORY AND DIGESTIVE CONDITIONS
FR2751223B1 (en) 1996-07-19 1998-12-04 Rhone Merieux FELIN POLYNUCLEOTIDE VACCINE FORMULA
FR2751229B1 (en) 1996-07-19 1998-11-27 Rhone Merieux POLYNUCLEOTIDE VACCINE FORMULA IN PARTICULAR AGAINST RESPIRATORY PATHOLOGY OF CATTLE
FR2751228B1 (en) 1996-07-19 1998-11-20 Rhone Merieux BOVINE POLYNUCLEOTIDE VACCINE FOR INTRADERMAL ROUTE
DK0904392T3 (en) 1996-10-17 2001-04-30 Oxford Biomedica Ltd Retroviral vectors
US6231859B1 (en) 1996-12-02 2001-05-15 Aquila Biopharmaceuticals, Inc. Saponin adjuvant compositions
FR2757061B1 (en) 1996-12-16 1999-03-26 Rhone Merieux AVIAN RECOMBINANT LIVING VACCINE USING AVIAN INFECTIOUS LARYNGOTRACHEITIS VIRUS AS A VECTOR
FR2758986B1 (en) 1997-01-31 1999-04-30 Rhone Merieux AVIAN RECOMBINANT LIVING VACCINE USING AVIAN INFECTIOUS LARYNGOTRACHEITIS VIRUS AS A VECTOR
US6183752B1 (en) 1997-02-05 2001-02-06 Pasteur Merieux Serums Et Vaccins Restenosis/atherosclerosis diagnosis, prophylaxis and therapy
US6368603B1 (en) 1997-03-05 2002-04-09 Merial Limited Lyme combination compositions and uses
US6004777A (en) 1997-03-12 1999-12-21 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
US5990091A (en) 1997-03-12 1999-11-23 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
US20020136722A1 (en) 1997-06-18 2002-09-26 Heath Andrew William Vaccination method
US6348450B1 (en) 1997-08-13 2002-02-19 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom and uses thereof
EP2050465B1 (en) 1997-08-29 2014-06-11 Antigenics Inc. Compositions comprising the adjuvant QS-21 and polysorbate or cyclodextrin as excipient
FR2781159B1 (en) 1998-07-06 2000-10-06 Merial Sas CIRCOVIRUS VACCINE AND PIG PARVOVIRUS
US6391314B1 (en) 1997-10-03 2002-05-21 Merial Porcine circoviruses vaccines diagnostic reagents
US6224882B1 (en) 1997-11-07 2001-05-01 Protein Science Corp. Insect cells or fractions as adjuvant for antigens
CA2315269A1 (en) 1997-12-22 1999-07-01 Oxford Biomedica (Uk) Limited Equine infectious anaemia virus (eiav) based
US6693086B1 (en) 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
US6103526A (en) 1998-10-08 2000-08-15 Protein Sciences Corporation Spodoptera frugiperda single cell suspension cell line in serum-free media, methods of producing and using
US6497883B1 (en) 1999-06-10 2002-12-24 Merial Porcine circovirus recombinant poxvirus vaccine
WO2001095919A2 (en) 2000-06-15 2001-12-20 The Governement Of The United States Of America, As Represented By The Secretary Departement Of Hea Lth And Human Services A recombinant non-replicating virus expressing gm-csf and uses thereof to enhance immune responses

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002012281A2 (en) * 2000-08-03 2002-02-14 Johns Hopkins University Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
BRULET JEAN-MARC ET AL: "DNA vaccine encoding endosome-targeted human papillomavirus type 16 E7 protein generates CD4+ T cell-dependent protection.", EUROPEAN JOURNAL OF IMMUNOLOGY FEB 2007, vol. 37, no. 2, February 2007 (2007-02-01), pages 376 - 384, XP002714217, ISSN: 0014-2980 *
CHENG WEN-FANG ET AL: "Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen", JOURNAL OF CLINICAL INVESTIGATION, AMERICAN SOCIETY FOR CLINICAL INVESTIGATION, US, vol. 108, no. 5, 1 September 2001 (2001-09-01), pages 669 - 678, XP002479997, ISSN: 0021-9738 *
FREIGANG STEFAN ET AL: "A lymphocytic choriomeningitis virus glycoprotein variant that is retained in the endoplasmic reticulum efficiently cross-primes CD8(+) T cell responses.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 14 AUG 2007, vol. 104, no. 33, 14 August 2007 (2007-08-14), pages 13426 - 13431, XP002714214, ISSN: 0027-8424 *
JI HONGXIU ET AL: "Targeting human papillomavirus type 16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine human papillomavirus type 16 E7-expressing tumors", HUMAN GENE THERAPY, MARY ANN LIEBERT, NEW YORK ,NY, US, vol. 10, no. 17, 20 November 1999 (1999-11-20), pages 2727 - 2740, XP002956558, ISSN: 1043-0342, DOI: 10.1089/10430349950016474 *
KOEN OOSTERHUIS ET AL: "Preclinical development of highly effective and safe DNA vaccines directed against HPV 16 E6 and E7", INTERNATIONAL JOURNAL OF CANCER, vol. 129, no. 2, 15 July 2011 (2011-07-15), pages 397 - 406, XP055031276, ISSN: 0020-7136, DOI: 10.1002/ijc.25894 *
OOSTERHUIS KOEN ET AL: "Rational design of DNA vaccines for the induction of human papillomavirus type 16 E6- and E7-specific cytotoxic T-cell responses.", HUMAN GENE THERAPY DEC 2012, vol. 23, no. 12, December 2012 (2012-12-01), pages 1301 - 1312, XP002714216, ISSN: 1557-7422 *
RIVERA V M ET AL: "Regulation of protein secretion through controlled aggregation in the endoplasmic reticulum.", SCIENCE (NEW YORK, N.Y.) 4 FEB 2000, vol. 287, no. 5454, 4 February 2000 (2000-02-04), pages 826 - 830, XP002714215, ISSN: 0036-8075 *
STEVENSON FREDA K ET AL: "DNA fusion gene vaccines against cancer: from the laboratory to the clinic.", IMMUNOLOGICAL REVIEWS JUN 2004, vol. 199, June 2004 (2004-06-01), pages 156 - 180, XP002714213, ISSN: 0105-2896 *
WU A ET AL: "Innovative DNA vaccine for human papillomavirus (HPV)-associated head and neck cancer.", GENE THERAPY MAR 2011, vol. 18, no. 3, March 2011 (2011-03-01), pages 304 - 312, XP002714212, ISSN: 1476-5462 *

Also Published As

Publication number Publication date
WO2013093629A2 (en) 2013-06-27

Similar Documents

Publication Publication Date Title
MX2013004817A (en) Inflammatory disease.
WO2015138357A3 (en) Compositions useful in treatment of otc deficency
PH12015500274B1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
WO2013130703A3 (en) Inhibitors of hepatitis b virus covalently closed circular dna formation and their method of use
WO2012047856A3 (en) Novel inhibitors of secretion of hepatitis b virus antigens
NZ709260A (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
GB201118656D0 (en) New compounds
MY166557A (en) Quinazoline derivatives for the treatment of viral infections and further diseases
MX2012013731A (en) Vaccines comprising cholesterol and cpg as sole adjuvant - carrier molecules.
MX349004B (en) New compounds.
MX347734B (en) S100a4 antibodies and therapeutic uses thereof.
PH12015500713B1 (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
WO2011086093A3 (en) Pharmaceutical compositions for oral administration of insulin peptides
WO2012119070A3 (en) Silicone-based ophthalmic formulations
MX2013013801A (en) Immunostimulatory oligodeoxynucleotides.
WO2009009759A3 (en) Yersinia pestis antigens, vaccine compositions, and related methods
IN2014DN03054A (en)
NZ708016A (en) Lyophilized preparations of melphalan flufenamide
WO2009135199A3 (en) Vaccine compositions and methods
MX2013003245A (en) Bvdv vaccine.
WO2014140166A3 (en) Vaccine
WO2014100857A8 (en) Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy
EP2785335B8 (en) Methods and pharmaceutical compositions for the treatment of darier disease
TN2012000217A1 (en) The use of an l3 and/or l5 source as a vaccine or as a diagnostic for a parasitic disease
WO2010135585A3 (en) Engineered type iv pilin of clostridium difficile

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12837640

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 12837640

Country of ref document: EP

Kind code of ref document: A2